Xenova Phase II HPV data

Xenova (LSE:XEN; XNVA) said that in a Phase II study in 29 patients, the combination of its TA-CIN and TA-HPV therapeutic vaccines against human papillomavirus (HPV)-associated ano-genital intraepithelial neoplasia (AGIN) was safe and well tolerated. Fifteen of 29 women (60%) with stable, non-cervical disease showed evidence of symptomatic improvement in the open-label U.K. trial. Five women (19%) had partial responses, defined as a lesion area reduction of at least 50%, and one woman had a complete response. Also, five women (20%) were HPV16-negative at the end of the study. Two patients with vaginal intra-epithelial neoplasia showed a partial response. Results were presented at the British Society for Colposcopy & Cervical Pathology meeting in Manchester. ...